Share on StockTwits
 

CryoLife (NYSE:CRY) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued on Tuesday, AnalystRatings.NET reports. They currently have a $12.40 price objective on the stock. Zacks‘ price target would indicate a potential upside of 5.71% from the stock’s previous close.

CryoLife (NYSE:CRY) traded up 3.07% during mid-day trading on Tuesday, hitting $12.0899. 145,445 shares of the company’s stock traded hands. CryoLife has a 52-week low of $5.52 and a 52-week high of $11.33. The stock has a 50-day moving average of $10.74 and a 200-day moving average of $8.33. The company has a market cap of $333.8 million and a price-to-earnings ratio of 35.76.

CryoLife (NYSE:CRY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.07. The company had revenue of $36.30 million for the quarter, compared to the consensus estimate of $35.51 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. Analysts expect that CryoLife will post $0.60 EPS for the current fiscal year.

CryoLife, Inc (NYSE:CRY) is a biological medical device company.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.